SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

10 May 2022 Evaluate
The company witnessed a 11.44% growth in the revenue at Rs. 29466.10 millions for the quarter ended March 2022 as compared to Rs. 26442.00 millions during the year-ago period.A humble growth in net profit of 13.50% reported in the quarter ended March 2022 to Rs. 4763.00  millions from Rs. 4196.60 millions.Operating profit for the quarter ended March 2022 rose to 7039.60 millions as compared to 6875.80 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 29466.10 26442.00 11.44 130917.90 113027.10 15.83 130917.90 113027.10 15.83
Other Income 3163.10 493.30 541.21 6667.00 2302.80 189.52 6667.00 2302.80 189.52
PBIDT 7039.60 6875.80 2.38 40331.70 32976.90 22.30 40331.70 32976.90 22.30
Interest 57.80 88.40 -34.62 269.30 450.70 -40.25 269.30 450.70 -40.25
PBDT 6981.80 6787.40 2.86 40062.40 32526.20 23.17 40062.40 32526.20 23.17
Depreciation 1168.20 1177.50 -0.79 4600.10 4686.20 -1.84 4600.10 4686.20 -1.84
PBT 5813.60 5609.90 3.63 35462.30 27840.00 27.38 35462.30 27840.00 27.38
TAX 1050.60 1413.30 -25.66 8568.40 7393.50 15.89 8568.40 7393.50 15.89
Deferred Tax -35.00 92.80 -137.72 -304.00 -169.20 79.67 -304.00 -169.20 79.67
PAT 4763.00 4196.60 13.50 26893.90 20446.50 31.53 26893.90 20446.50 31.53
Equity 1613.60 1612.90 0.04 1613.60 1612.90 0.04 1613.60 1612.90 0.04
PBIDTM(%) 23.89 26.00 -8.13 30.81 29.18 5.59 30.81 29.18 5.59

Cipla Share Price

1234.00 -4.30 (-0.35%)
20-Apr-2026 12:08 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.50
Dr. Reddys Lab 1236.80
Cipla 1234.00
Zydus Lifesciences 938.50
Lupin 2323.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×